Osiris Therapeutics and Genzyme struck a marketing deal for two adult stem cell treatments, Prochymal and Chondrogen, both of which are in clinical trials. This important deal will strengthen Genzyme’s late stage pipeline in transplantation rejection and inflammatory disease.